
Full INTerpath-001 results show the individualized mRNA therapy plus pembrolizumab reduced recurrence risk in resected stage IIB-IV melanoma.
Supplements and Featured Publications
This clinical brief provides a background on DED and reviews DED treatment and challenges associated with prescription eye drops.






